Czechia vs North Macedonia: Prevalence rate of obesity in adults
Czechia
26.3%
in 2024
North Macedonia
26.8%
in 2024
Czechia rank
80th
North Macedonia rank
79th
Prevalence rate of obesity in adults over time
- Czechia
- North Macedonia
How they compare
North Macedonia currently reports 26.8% against 26.3% in Czechia, a difference of 0.5%.
The two have swapped places 1 time across 45 shared years of data; in 1980 it was Czechia ahead.
Czechia ranks 80th and North Macedonia ranks 79th of 199 countries.
Across the 5 decades both report, Czechia averaged higher in 3 and North Macedonia in 2.
Head to head by decade
| Decade | Czechia | North Macedonia | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 20.2% | 14.3% | 5.8% | Czechia |
| 1990s | 19.2% | 16.1% | 3.0% | Czechia |
| 2000s | 19.9% | 19.4% | 0.5% | Czechia |
| 2010s | 22.9% | 23.4% | 0.5% | North Macedonia |
| 2020s | 25.6% | 26.1% | 0.5% | North Macedonia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of obesity in adults, Czechia or North Macedonia?
- North Macedonia, at 26.8% against 26.3% in Czechia as of 2024.
- What is the difference in prevalence rate of obesity in adults between Czechia and North Macedonia?
- 0.5%, with North Macedonia ahead.
- How many years of comparable data are there for Czechia and North Macedonia?
- 45 years are reported by both, from 1980 to 2024.
- How do Czechia and North Macedonia rank globally for prevalence rate of obesity in adults?
- Czechia ranks 80th and North Macedonia ranks 79th of 199 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of obesity in adults. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated prevalence of obesity in adults, based on general population surveys and statistical modeling. Obesity is a risk factor for chronic complications, including cardiovascular disease, and premature death.